Tillotts Pharma AG, the Rheinfelden-based specialty pharmaceutical company, has signed an agreement on 23 October 2026 to acquire Haupt Pharma Wülfing GmbH (HPW), a pharmaceutical manufacturer based in Gronau, Germany.

The announcement was made public on 26 October 2026.

Tillotts acquisition to expand pharmaceutical production

The acquisition is intended to expand Tillotts' pharmaceutical production capacities and strengthen its own value creation. The parties have agreed not to disclose the purchase price.

The transaction remains subject to conditions customary for deals of this kind, including the granting of the necessary regulatory approvals.

A long-standing manufacturing partner

The Gronau site has been a key manufacturer of Asacol, a core product in the Tillotts portfolio, for many years. By bringing the site into its own ownership, Tillotts will in the future be able to directly manage production capacity, planning, and quality, and flexibly tailor production to market requirements.

Thomas A. Tóth von Kiskér, CEO of the Tillotts Group, framed the move in terms of supply reliability. "Reliability is essential to us. Patients and our partners rely on us to supply them safely with high-quality products. With the Gronau site, we are strengthening our ability to live up to that trust over the long term," he said in the announcement.

According to the company, the acquisition forms part of Tillotts' long-term strategy as a growing specialty pharmaceutical company with high-performance manufacturing sites. It is intended to support the long-term supply of the existing portfolio, which is currently marketed in around 65 countries.

USD 25.7 million modernisation programme

Tillotts plans to invest around USD 25.7 million in the Gronau site over the coming years.

The company says this investment is intended to modernise the site, further improve quality and efficiency, and lay the foundations for future growth.

More than a century of pharmaceutical history

The Gronau site brings with it a pharmaceutical history spanning more than 100 years. Its capabilities include the development, manufacture, and packaging of solid dosage forms; analytical and formulation services; and the packaging and distribution of clinical trial supplies.

Once the takeover is complete, around 280 employees will become part of the Tillotts Group, which already employs 370 people across Europe. Tillotts describes the specialist knowledge and many years of experience of the Gronau staff as key to maintaining and further developing the site's expertise in a targeted manner.

"The strength of this site lies in its people and their expertise. We look forward to welcoming the employees to Tillotts and building on this experience together," said Tóth von Kiskér.

Context: Tillotts and the Zeria Group

Tillotts Pharma AG is part of the Japanese Zeria Group and describes itself as a fast-growing specialty pharmaceutical company with 370 employees in Switzerland and abroad. Its focus is the development, acquisition, and commercialisation of innovative pharmaceutical products for the digestive system.

The company markets its own products for the treatment of inflammatory bowel disease (IBD) and Clostridioides difficile infection (CDI), as well as in-licensed products, in around 65 countries through its European subsidiaries and a global network of partners.

Zeria Pharmaceutical Co., Ltd., founded in 1955 and headquartered in Tokyo, focuses on the research and development, manufacture, and sale of prescription medicines and over-the-counter products.

The company is listed on the Prime Market of the Tokyo Stock Exchange under stock code 4559 and holds a leading position in gastroenterology in Japan.

Deal conditions and next steps

The acquisition remains subject to the customary closing conditions, including regulatory approvals. Until those approvals are granted and the transaction completes, the Gronau site continues to operate as Haupt Pharma Wülfing GmbH.

Further details, including the financial terms of the deal, have not been made public.

Stay Ahead of Germany's Chemical Sector Developments

Whether you're focusing on chemical production, distribution, or innovative initiatives across the nation, one thing is clear: significant projects are being announced, tendered, and awarded every single day. Missing them means losing them.

The Global Project Tracking (GPT) platform by Blackridge Research provides a real-time, curated overview of project activity in Germany's chemical sector, ensuring your business development team is always aware of where demand is moving ahead of market reactions.

From feasibility-stage initiatives to fully funded developments, every opportunity is captured, categorized, and delivered to you in real time.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Book a Free Demo of the Global Project Tracking (GPT) platform by Blackridge Research and turn Germany's chemical pipeline into your competitive advantage.